Gemina Laboratories Ltd.
GLABF
$0.7362
$0.0060.82%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 320.60K | 381.60K | 428.70K | 373.60K | 437.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 601.90K | 671.10K | 581.90K | 769.20K | 642.10K |
| Operating Income | -601.90K | -671.10K | -581.90K | -769.20K | -642.10K |
| Income Before Tax | -632.90K | -702.80K | -608.20K | -564.20K | -860.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -632.90K | -702.80K | -608.20K | -564.20K | -860.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -632.90K | -702.80K | -608.20K | -564.20K | -860.20K |
| EBIT | -601.90K | -671.10K | -581.90K | -769.20K | -642.10K |
| EBITDA | -599.90K | -667.30K | -578.00K | -765.50K | -637.80K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 74.51M | 73.54M | 73.33M | 75.06M | 73.33M |
| Average Diluted Shares Outstanding | 74.51M | 73.54M | 73.33M | 75.06M | 73.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
